Evidence-based oxygen therapy: Missed and future opportunities  by Lacasse, Y. et al.
Rev Port Pneumol. 2012;18(6):257--259
www.revportpneumol.org
EDITORIAL
Evidence-based  oxygen  therapy:  Missed and  future  opportunitiesOxigenoterapia  baseada  na  evidência:  Oportunidades  perdidas  e  futuras
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pTwo  landmark  trials  conducted  more  than  30  years  ago
provided  scientiﬁc  evidence  that,  under  very  speciﬁc  cir-
cumstances,  long-term  oxygen  therapy  (LTOT)  may  prolong
life.1,2 These  two  trials  targeted  patients  with  chronic
obstructive  pulmonary  disease  (COPD)  and  severe  daytime
hypoxemia  documented  by  direct  arterial  blood  gas  mea-
surement.
Although  the  survival  beneﬁts  of  LTOT  in  COPD  are
real,  home  oxygen  is  not  a  panacea.  In  the  British  Medi-
cal  Research  Council’s  trial,  500  days  elapsed  before  any
effect  of  LTOT  on  survival  appeared,  when  compared  to  no
oxygen  therapy  at  all.1 Overall,  at  5-year  follow-up,  those
who  received  oxygen  had  improved  survival:  19  of  42  (42%)
had  died,  compared  to  30  of  the  45  control  patients  (66%).
The  difference  (24%)  corresponds  to  a  number  needed  to
treat  (NNT)  of  5,  which  means  that  5  patients  must  receive
oxygen  during  5  years  in  order  to  prevent  one  death  over
the  same  period.  Similarly,  the  American  Nocturnal  Oxygen
Therapy  trial  randomly  assigned  patients  to  receive  oxygen
for  either  12  h  a  day  (nocturnal  group)  or  24  h  a  day  (con-
tinuous  group).2 The  latter  group  actually  received  oxygen
for  an  average  of  19  h  a  day.  All  received  oxygen  therapy
during  sleep.  At  24  months,  the  overall  mortality  in  the
continuous  group  was  22.4%,  whereas  it  was  40.8%  in  the
nocturnal  group  (absolute  difference:  18.4%;  p  =  0.01).
The  corresponding  NNT  was  therefore  6.
The  good  news  from  both  trials  was  that  ‘‘oxygen
saves  lives’’.  From  this  moment,  oxygen  therapy  became
a  standard  of  care,  and  conﬁrmatory  trials  would  be  consid-
ered  by  many  as  unethical.  Unfortunately,  beyond  survival,
the  effects  of  LTOT  on  quality  of  life  remain  largely  unex-
plored  in  randomized  controlled  trials.  Both  the  British
and  the  American  trials  were  conducted  before  the  era
of  quality-of-life  questionnaires.  Although  suggestion  from
uncontrolled  studies  has  been  made  that  oxygen  therapy
improves  quality  of  life,3 clinical  experience  rather  suggests
that  LTOT  may  limit  the  patients’  ability  to  remain  active
and  may  be  detrimental  to  the  rehabilitation  process.
Thereafter,  oxygen  therapy  gained  widespread  accep-
tance  by  ofﬁcial  organizations  for  treatment  of  most  chronic
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http://dx.doi.org/10.1016/j.rppneu.2012.08.001ardio-respiratory  conditions  complicated  by  severe  hypox-
mia,  even  if  proof  of  efﬁcacy  is  lacking.  These  conditions
ow  largely  go  beyond  COPD  and  include,  among  others,
ystic  ﬁbrosis,4 interstitial  lung  diseases,5 and  pulmonary
rterial  hypertension.6 In  only  rare  exceptions  (such  as
besity  hypoventilation7 and  chronic  heart  failure8),  the
ndication  of  oxygen  in  patients  with  severe  hypoxemia  is
uestioned.  Also,  new  indications  of  oxygen  therapy  in  COPD
such  as  nocturnal  oxygen  therapy  in  patients  with  isolated
octurnal  oxygen  desaturation,  or  ambulatory  oxygen  to  cor-
ect  exercise-induced  desaturation)  have  emerged.  To  these
xtended  indications  of  home  oxygen,  one  must  add  that,
ven  in  COPD,  inappropriate  prescriptions  of  home  oxygen
herapy  are  not  unusual.9 Oxygen  is  everywhere.
Home  oxygen  therapy  is  very  expensive.  For  instance,
n  the  Canadian  cohort  of  the  Confronting  COPD  Survey
3265  individuals;  mean  age:  63  years;  44%  female),  oxygen
herapy  accounted  for  17%  of  the  entire  annual  direct  costs
f  COPD  care.10 Also,  home  oxygen  therapy  imposes  sacri-
ces  on  patients  and  their  families.  It  is  therefore  surprising
hat  it  is  so  readily  accepted  by  patients,  health  care  profes-
ionals  and  payers,  despite  the  lack  of  evidence  to  support
ts  use  in  most  circumstances.  Why  is  that  so?  In  addition
o  being  safe  and  readily  available,  the  problem  with  oxy-
en  is  that  its  prescription  always  makes  sense:  if  oxygen
esaturation  exists,  its  correction  should  help.
This  reasoning  was  common  before  the  introduction
f  ‘‘evidence-based  medicine’’,  when  the  study  and
nderstanding  of  basic  mechanisms  of  disease  and  patho-
hysiologic  principles  were  considered  sufﬁcient  to  guide
linical  practice.11 A  famous  example  proved  the  contrary.
ince  ventricular  arrhythmias  are  an  important  cause  of
eath  following  acute  myocardial  infarction,  their  sup-
ression  was  expected  to  decrease  mortality.  The  Cardiac
rrhythmia  Suppression  trial  (CAST)  was  stopped  early  after
atients  allocated  to  receive  potent  anti-arrhythmic  drugs
ere  found  to  have  an  increased  mortality  rate  when
ompared  to  those  receiving  placebo.12 Similar  examples,
lthough  less  dramatic,  exist  in  the  ﬁeld  of  oxygen  therapy.
or  instance,  although  oxygen  corrects  oxygen  desaturation
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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nd  improves  walked  distance  in  patients  with  COPD
nd  exercise-induced  desaturation  in  laboratory  testing,13
ther  trials  have  failed  to  demonstrate  any  long-term
eneﬁt.14--17
Before  the  introduction  of  ‘‘evidence-based  medicine’’,
nother  assumption  guiding  clinical  practice  was  that  unsys-
ematic  observations  from  clinical  experience  were  a  valid
ay  of  building  and  maintaining  knowledge  about  the  efﬁ-
acy  of  treatment.11 Clinicians’  memory  is  often  selective.
he  observations  they  recall  are  often  anecdotal  and  limited
o  their  best  or  worst  experiences.  In  the  case  of  oxygen
herapy,  bad  experiences  seldom  occur.  The  consequence  is
hat  prescriptions  of  home  oxygen  therapy  are  well  anchored
nto  clinical  practice  and  almost  never  challenged.
Twenty  years  ago,  a  shift  of  paradigm  operated.
vidence-based  medicine  was  put  forward.18 Evidence  based
edicine  is  the  conscientious,  explicit,  and  judicious  use
f  current  best  evidence  in  making  decisions  about  the
are  of  individual  patients.19 The  assumptions  of  the  new
aradigm  were  then  described  as  follows:  (1)  the  study
nd  understanding  of  mechanisms  of  disease  are  necessary
ut  insufﬁcient  guides  for  clinical  practice;  (2)  systematic
bservations  increase  the  conﬁdence  clinicians  can  have  in
nowledge  about  efﬁcacy  of  treatments;  (3)  understanding
ertain  rules  of  evidence  is  necessary  to  correctly  interpret
he  medical  literature.11
This  new  paradigm  guided  us  in  the  development
nd  implementation  of  the  International  Nocturnal  Oxy-
en  (INOX)  trial,  a  multi-centre,  randomized,  placebo-
ontrolled  trial  of  nocturnal  oxygen  therapy  in  COPD
ClinicalTrtials.gov  id:  NCT01044628).  Prior  observations
uggested  that  nocturnal  oxygen  desaturation  may  acceler-
te  the  natural  progression  of  COPD  toward  its  end  stages
f  severe  hypoxemia,  right  heart  failure,  and  death.20,21
ntil  recently,  it  was  often  recommended  in  Canada  (and
lsewhere  around  the  world)  that  nocturnal  oxygen  be
onsidered  if  desaturation  occurs  for  protracted  periods.
owever,  current  evidence  from  two  small  randomized  con-
rolled  trials22,23 and  their  meta-analysis24 does  not  support
his  recommendation.  The  cost-effectiveness  of  nocturnal
xygen  is  unknown.  The  INOX  trial,  in  which  4  clinical  sites
n  Portugal  (Matosinhos,  Vila  Nova  de  Gaia,  Coimbra  and
isboa)  participate,  is  intended  to  address  this  important
linical  question.
Of  note,  even  when  data  from  randomized  trials  exist,  its
ranslation  into  clinical  practice  may  be  problematic.  This  is
een  especially  in  the  case  of  negative  trials.  Our  experience
ith  a  randomized  trial  of  ambulatory  oxygen  in  oxygen-
ependent  patients  with  COPD  illustrates  this  situation.25 In
 one-year,  randomized,  three-period,  crossover  trial,  we
llocated  24  patients  to  one  of  the  6  possible  sequences
enerated  by  3  interventions:  (1)  standard  therapy  (home
xygen  therapy  with  an  oxygen  concentrator  only);
2)  standard  therapy  plus  as-needed  ambulatory  oxygen;
3)  standard  therapy  plus  ambulatory  compressed  air.  The
omparison  of  ambulatory  oxygen  vs.  ambulatory  com-
ressed  air  was  double  blind.  The  main  outcomes  were
uality  of  life,  exercise  tolerance  and  daily  duration  of  expo-
ure  to  oxygen.  The  trial  was  stopped  prematurely  after  a
lanned  interim  analysis.  On  average,  the  patients  used  few
mbulatory  cylinders  and  ambulatory  oxygen  had  no  effect
t  all  on  any  of  the  outcomes.  Our  results  did  not  supportEDITORIAL
he  widespread  provision  of  ambulatory  oxygen  to  patients
ith  oxygen-dependent  COPD.
The  results  of  our  trial  challenged  the  recommendation
hat  active  patients  receiving  LTOT  should  have  both  station-
ry  and  mobile  systems  of  oxygen  delivery.26,27 The  sample
ize  of  our  trial  was  small.  However,  for  both  quality  of  life
nd  exercise  capacity,  the  95%  conﬁdence  intervals  around
he  mean  treatment  effect  included  zero  (i.e.,  no  effect)
nd  excluded  what  is  usually  considered  as  the  minimal  clin-
cally  important  difference,  a  clear  demonstration  that  the
egative  results  were  not  from  a lack  of  power  to  detect
 clinically  signiﬁcant  difference.  We  rather  interpreted  the
egative  results  as  a  real  indication  of  no  beneﬁt  from  ambu-
atory  oxygen  under  the  circumstances  of  the  study.  Our
esults  were  recently  conﬁrmed  by  a  related  trial.28 How-
ver,  we  are  still  facing  clinicians’  reluctance,  even  in  our
wn  institution,  to  limit  the  prescriptions  of  ambulatory  oxy-
en  in  oxygen-dependent  COPD  patients.
Home  oxygen  therapy  still  offers  a  multitude  of  research
pportunities  in  COPD.29 The  INOX  trial  is  only  one  of  them.
he  effects  of  home  oxygen  therapy  in  most  cardiopul-
onary  conditions  (including  interstitial  lung  diseases,
ystic  ﬁbrosis,  pulmonary  arterial  hypertension  and  chronic
eart  failure)  remain  unexplored.  Randomized  trials  repre-
ent  the  most  powerful  method  to  address  these  important
linical  questions.  Cost-effectiveness  analyses  are  also
eeded.  Suggestion  has  been  made  that  multicenter  clini-
al  research  networks  should  be  established  to  perform  such
linical  trials.30 Such  efforts  are  challenging  as  they  require
ime,  money  and  commitment  from  all  investigators  to  bring
he  clinical  trials  to  their  ends.  However,  this  investment  is
ertainly  worth  it  for  the  patients  and  those  who  will  have
o  ﬁnancially  support  LTOT.
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